248P - Substantial RUNX3 expression and co-existence with EZH2 in esophageal cancer: a new finding in Indian esophageal cancer patients

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Oesophageal Cancer
Translational Research
Presenter Asad Rehman
Citation Annals of Oncology (2016) 27 (suppl_9): ix68-ix85. 10.1093/annonc/mdw582
Authors A.U. Rehman1, M.A. Iqbal2, S. Saikia3, P.K. Mishra4, S.S. Saluja4, S. Medhi3, S.A. Husain5
  • 1Biosciences, JAMIA MILLIA ISLAMIA, 110025 - Delhi/IN
  • 2Department Of Biotechnology, JAMIA MILLIA ISLAMIA, 110025 - Delhi/IN
  • 3Department Of Bioengineering And Technology, GAUHATI UNIVERSITY, 781014 - Guwahati/IN
  • 4G I Surgery, Govind Ballabh Pant institute of Postgraduate Medical Education & Research, 110002 - New Delhi/IN
  • 5Department Of Biosciences, JAMIA MILLIA ISLAMIA, 110025 - Delhi/IN



Runt related transcription factor3 (RUNX3) is considered as a tumor suppressor gene (TSG) that functions through the TGF-β dependent apoptosis. Hypermethylation of CpG islands of RUNX3 promoter and overexpression of enhancer of zeste homolog 2 (EZH2) has been suggested to downregulate RUNX3 in cancer. Here, we studied the expression of RUNX3 and EZH2 in tumors along with adjacent normal mucosa from 58 esophageal cancer (CaEs) patients of India and its mechanism of downregulation in CaEs.


mRNA level, protein expression and cellular localization of EZH2 and RUNX3 were analyzed using real-time PCR, Western blot and immunohistochemistry, respectively. DNA methylation was also assessed by methylation specific-PCR. Clinicopathological parameters were recorded and correlated with the EZH2 and RUNX3 expression.


Out of 58 patients, 89.6% were squamous cell carcinoma and 11.4% were adenocarcinoma. 91.3% patients had locally advanced tumor whereas 8.7% were metastatic. 10.3% patients had upper CaEs, 48.3% had in the middle third and 41.4% had esophageal cancer in the lower third region. Out of 58 CaEs 25(43.1%) patients had stage I or stage II cancer whereas 33 (56.9%) patients had stage III or stage IV cancer. However, none of these parameters were found to be significantly correlated with the RUNX3 or EZH2 expression. Compared to normal mucosa, a significant increase in expression of RUNX3 mRNA in 34/58 patients (p 


The data of this study provide new insights into the biology of RUNX3 and questions our current understanding of the role of RUNX3 in cancer.

Clinical trial indentification

Legal entity responsible for the study

Department Of Biotechnology (DBT NER BPMC)


Department Of Biotechnoloy (DBT NER BPMC)


All authors have declared no conflicts of interest.